The TransCatheter Valve and Vessels Trial

Exclusion Criteria

• •1. Patients in cardiogenic shock or acute heart failure, requiring inotropic agents during procedure and/or i.v. diuretics \<48 hours before procedure
• •2. Left ventricular ejection fraction \<30%
• •3. Concomitant presence of other than aortic valve disease requiring intervention
• •4. Previous CABG, SAVR, TAVI or thoracotomy for any other reason
• •5. Bicuspid or unicuspid aortic valve
• •6. Recent myocardial infarction (less than 2 weeks)
• •7. Involvement of left main trifurcation (all three branches being larger than 2 mm)
• •8. Expected total stent length more 60mm per vessel
• •9. FFR measurement judged impossible
• •10. Life expectancy \<1 year
• •11. Known malignancy
• •12. Contraindication for dual antiplatelet therapy or expected surgical intervention requiring interruption of Dual Antiplatelet Therapy (DAPT) in the first 6 months
• •13. Reduced renal function (Glomerular Filtration Rate (GFR) \<29 ml/min/1.73m2; Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5)
• •14. Previous disabling stroke, Transient Ischemic Attack (TIA) in the last 6 months, or known severe stenosis of carotid or vertebral arteries
• •15. Participation in other investigational clinical trials